One obstacle to the successful delivery of nanodrugs into solid tumors is the heterogeneity of an enhanced permeability and retention (EPR) effect as a result of occluded or embolized tumor blood vessels. Therefore, the augmentation of the EPR effect is critical for satisfactory anticancer nanomedicine. In this study, we focused on one vascular mediator involved in the EPR effect, carbon monoxide (CO), and utilized two CO generating agents, one is an extrinsic CO donor (SMA/CORM2 micelle) and another is an inducer of endogenous CO generation via heme oxygenase-1 (HO-1) induction that is carried out using pegylated hemin. Both agents generated CO selectively in solid tumors, which resulted in an enhanced EPR effect and a two- to three-folds increased tumor accumulation of nanodrugs. An increase in drug accumulation in the normal tissue did not occur with the treatment of CO generators. In vivo imaging also clearly indicated a more intensified fluorescence of macromolecular nanoprobe in solid tumors when combined with these CO generators. Consequently, the combination of CO generators with anticancer nanodrugs resulted in an increased anticancer effect in the different transplanted solid tumor models. These findings strongly warrant the potential application of these CO generators as EPR enhancers in order to enhance tumor detection and therapy using nanodrugs.

Biodynamics Research Foundation Kumamoto 862 0954 Japan

Department of General Surgery Sheng Jing Hospital China Medical University Shenyang 110011 China

Department of Microbiology Graduate School of Medical Sciences Kumamoto University Kumamoto 860 8556 Japan

Faculty of Pharmaceutical Sciences Sojo University Kumamoto 860 0082 Japan

Institute of Macromolecular Chemistry Czech Academy of Sciences Prague 16206 Czech Republic

Zobrazit více v PubMed

Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392. PubMed

Fang J., Nakamura H., Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011;63:136–151. doi: 10.1016/j.addr.2010.04.009. PubMed DOI

Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011;63:131–135. doi: 10.1016/j.addr.2010.03.011. PubMed DOI

Duncan R. Polymer therapeutics: Top 10 selling pharmaceuticals—What next? J. Control. Release. 2014;190:371–380. doi: 10.1016/j.jconrel.2014.05.001. PubMed DOI

Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 2015;91:3–6. doi: 10.1016/j.addr.2015.01.002. PubMed DOI

Maeda H., Tsukigawa K., Fang J. A Retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: Next-generation chemotherapeutics and photodynamic therapy—Problems, solutions, and prospects. Microcirculation. 2016;23:173–182. doi: 10.1111/micc.12228. PubMed DOI

Maeda H. Polymer therapeutics and the EPR effect. J. Drug Target. 2017;25:781–785. doi: 10.1080/1061186X.2017.1365878. PubMed DOI

Islam W., Fang J., Imamura T., Etrych T., Subr V., Ulbrich K., Maeda H. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines. Mol. Cancer Ther. 2018;17:2643–2653. doi: 10.1158/1535-7163.MCT-18-0696. PubMed DOI

Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Tagawa S.T., Panageas K.S., DeAngelis L.M. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133:781–789. doi: 10.1182/blood-2018-06-860874. PubMed DOI PMC

Young A., Chapman O., Connor C., Poole C., Rose P., Kakkar A.K. Thrombosis and cancer. Nat. Rev. Clin. Oncol. 2012;9:437–449. doi: 10.1038/nrclinonc.2012.106. PubMed DOI

Reddel C.J., Tan C.W., Chen V.M. Thrombin generation and cancer: Contributors and consequences. Cancers. 2019;1:100. doi: 10.3390/cancers11010100. PubMed DOI PMC

Seki T., Fang J., Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci. 2009;100:2426–2430. doi: 10.1111/j.1349-7006.2009.01323.x. PubMed DOI PMC

Fang J., Liao L., Yin H., Nakamura H., Shin T., Maeda H. Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei. J. Pharm. Sci. 2014;103:3235–3243. doi: 10.1002/jps.24083. PubMed DOI

Kinoshita R., Ishima Y., Ikeda M., Kragh-Hansen U., Fang J., Nakamura H., Chuang V.T., Tanaka R., Maeda H., Kodama A. S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes. J. Control. Release. 2015;217:1–9. doi: 10.1016/j.jconrel.2015.08.036. PubMed DOI

Tahara Y., Yoshikawa T., Sato H., Mori Y., Zahangir M.H., Kishimura A., Mori T., Katayama Y. Encapsulation of a nitric oxide donor into a liposome to boost the enhanced permeation and retention (EPR) effect. MedChemComm. 2016;8:415–421. doi: 10.1039/C6MD00614K. PubMed DOI PMC

Motterlini R., Otterbein L.E. The therapeutic potential of carbon monoxide. Nat. Rev. Drug Discov. 2010;9:728–743. doi: 10.1038/nrd3228. PubMed DOI

Abraham N.G., Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol. Rev. 2008;60:79–127. doi: 10.1124/pr.107.07104. PubMed DOI

Fang J., Akaike T., Maeda H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis. 2004;9:27–35. doi: 10.1023/B:APPT.0000012119.83734.4e. PubMed DOI

Fang J., Qin H., Nakamura H., Tsukigawa K., Shin T., Maeda H. Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors. Cancer Sci. 2012;103:535–541. doi: 10.1111/j.1349-7006.2011.02178.x. PubMed DOI PMC

Yin H., Fang J., Liao L., Nakamura H., Maeda H. Styrene-maleic acid copolymer-encapsulated CORM2, a water-soluble carbon monoxide (CO) donor with a constant CO-releasing property, exhibits therapeutic potential for inflammatory bowel disease. J. Control. Release. 2014;187:14–21. doi: 10.1016/j.jconrel.2014.05.018. PubMed DOI

Fang J., Šubr V., Islam W., Hackbarth S., Islam R., Etrych T., Ulbrich K., Maeda H. N-(2-hydroxypropyl)methacrylamide polymer conjugated pyropheophorbide-a, a promising tumor-targeted theranostic probe for photodynamic therapy and imaging. Eur. J. Pharm. Biopharm. 2018;130:165–176. doi: 10.1016/j.ejpb.2018.06.005. PubMed DOI

Nakamura H., Etrych T., Ohkubo M., Fang J., Ulbrich K., Maeda H. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J. Control. Release. 2014;174:81–87. doi: 10.1016/j.jconrel.2013.11.011. PubMed DOI

Fang J., Qin H., Seki T., Nakamura H., Tsukigawa K., Shin T., Maeda H. Therapeutic potential of pegylated hemin for reactive oxygen species-related diseases via induction of heme oxygenase-1: Results from a rat hepatic ischemia/reperfusion injury model. J. Pharmacol. Exp. Ther. 2011;339:779–789. doi: 10.1124/jpet.111.185348. PubMed DOI

Takeuchi T., Iizumi Y., Yudasaka M., Kizaka-Kondoh S., Okazaki T. Characterization and biodistribution analysis of oxygen-doped single-walled carbon nanotubes used as in vivo fluorescence imaging probes. Bioconjug. Chem. 2019;30:1323–1330. doi: 10.1021/acs.bioconjchem.9b00088. PubMed DOI

Sundin A.M., Larsson J.E. Rapid and sensitive method for the analysis of carbon monoxide in blood using gas chromatography with flame ionisation detection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2002;766:115–121. doi: 10.1016/S0378-4347(01)00460-1. PubMed DOI

Iigo M., Nakagawa T., Ishikawa C., Iwahori Y., Asamoto M., Yazawa K., Araki E., Tsuda H. Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung. Br. J. Cancer. 1997;75:650–655. doi: 10.1038/bjc.1997.116. PubMed DOI PMC

Suzuki I., Iigo M., Ishikawa C., Kuhara T., Asamoto M., Kunimoto T., Moore M.A., Yazawa K., Araki E., Tsuda H. Inhibitory effects of oleic and docosahexaenoic acids on lung metastasis by colon-carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities. Int. J. Cancer. 1997;73:607–612. doi: 10.1002/(SICI)1097-0215(19971114)73:4<607::AID-IJC24>3.0.CO;2-4. PubMed DOI

Cassidy J., Newell D.R., Wedge S.R., Cummings J. Pharmacokinetics of high molecular weight agents. Cancer Surv. 1993;17:315–341. PubMed

Maeda H. The link between infection and cancer: Tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci. 2013;104:779–789. doi: 10.1111/cas.12152. PubMed DOI PMC

Maeda H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. J. Control. Release. 2012;164:138–144. doi: 10.1016/j.jconrel.2012.04.038. PubMed DOI

Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2012;88:53–71. doi: 10.2183/pjab.88.53. PubMed DOI PMC

Maeda H., Fang J., Inutsuka T., Kitamoto Y. Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. Int. Immunopharmacol. 2003;3:319–328. doi: 10.1016/S1567-5769(02)00271-0. PubMed DOI

Wu J., Akaike T., Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 1998;58:159–165. PubMed

Kwon I.K., Lee S.C., Han B., Park K. Analysis on the current status of targeted drug delivery to tumors. J. Control. Release. 2012;164:108–114. doi: 10.1016/j.jconrel.2012.07.010. PubMed DOI PMC

Kimura M., Konno T., Miyamoto Y., Kojima Y., Maeda H. Intracavitary administration: Pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses. Anticancer Res. 1998;18:2547–2550. PubMed

Von Maltzahn G., Park J.H., Lin K.Y., Singh N., Schwöppe C., Mesters R., Berdel W.E., Ruoslahti E., Sailor M.J., Bhatia S.N. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat. Mater. 2011;10:545–552. doi: 10.1038/nmat3049. PubMed DOI PMC

Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732–6740. doi: 10.1158/0008-5472.CAN-05-4199. PubMed DOI

Nemeth Z., Csizmadia E., Vikstrom L., Li M., Bisht K., Feizi A., Otterbein S., Zuckerbraun B., Costa D.B., Pandolfi P.P., et al. Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth. Oncotarget. 2016;7:23919–23932. doi: 10.18632/oncotarget.8081. PubMed DOI PMC

Wegiel B., Gallo D., Csizmadia E., Harris C., Belcher J., Vercellotti G.M., Penacho N., Seth P., Sukhatme V., Ahmed A., et al. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 2013;73:7009–7021. doi: 10.1158/0008-5472.CAN-13-1075. PubMed DOI PMC

Polymer theranostics with multiple stimuli-based activation of photodynamic therapy and tumor imaging

HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery